Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome

A. Iurlo, A. Nobili, Roberto Latagliata, Cristina Bucelli, F. Castagnetti, M. Breccia, Elisabetta Abruzzese, D. Cattaneo, C. Fava, D. Ferrero, A. Gozzini, M. Bonifacio, M. Tiribelli, P Pregno, Fabio Stagno, Paolo Vigneri, M. Annunziata, F. Cavazzini, Gianni Binotto, G. MansuetoS. Russo, F. Falzetti, E. Montefusco, Gabriele Gugliotta, Sergio Storti, Ada M. D'Addosio, Luigi Scaffidi, L. Cortesi, Michele Cedrone, A.R. Rossi, P. Avanzini, E. Mauro, A. Spadea, Francesca Celesti, Michelle G. Giglio, A. Isidori, Monica Crugnola, Elisabetta Calistri, Federica Sorà, Giovanna Rege-Cambrin, Giuseppe S. Sica, L. Luciano, S. Galimberti, E.M. Orlandi, M. Bocchia, M. Tettamanti, G. Alimena, G. Saglio, G. Rosti, P.M. Mannucci, A. Cortelezzi

Research output: Contribution to journalArticlepeer-review


Background: About 40% of all patients with chronic myeloid leukemia are currently old or very old. They are effectively treated with imatinib, even though underrepresented in clinical studies. Furthermore, as it happens in the general population, they often receive multiple drugs for associated chronic illnesses. Aim of this study was to assess whether or not in imatinib-treated patients aged > 75 years the exposure to polypharmacy (5 drugs or more) had an impact on cytogenetic and molecular response rates, event-free and overall survival, as well as on hematological or extra-hematological toxicity. Methods: 296 patients at 35 Italian hematological institutions were evaluated. Results: Polypharmacy was reported in 107 patients (36.1%), and drugs more frequently used were antiplatelets, diuretics, proton pump inhibitors, ACE-inhibitors, beta-blockers, calcium channel blockers, angiotensin II receptors blockers, statins, oral hypoglycemic drugs and alpha blockers. Complete cytogenetic response was obtained in 174 patients (58.8%), 78 (26.4%) within 6 month, 63 (21.3%) between 7 and 12 months. Major molecular response was obtained in 153 patients (51.7%), 64 (21.6%) within the 12 month. One hundred and twenty-eight cases (43.2%) of hematological toxicity were recorded, together with 167 cases (56.4%) of extra-hematological toxicity. Comparing patients exposed to polypharmacy to those without, no difference was observed pertaining to the dosage of imatinib, cytogenetic and molecular responses and hematological and extra-hematological toxicity. Conclusion: Notwithstanding the several interactions reported in the literature between imatinib and some of the medications considered herewith, this fact does not seem to have a clinical impact on response rate and outcome.
Original languageEnglish
Pages (from-to)80083-80090
Number of pages8
Issue number48
Publication statusPublished - 2016

Cite this